Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubit… Read more
Shenzhen Salubris Pharmaceuticals Co Ltd (002294) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.045x
Based on the latest financial reports, Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has a cash flow conversion efficiency ratio of 0.045x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥400.70 Million) by net assets (CN¥8.93 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shenzhen Salubris Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Shenzhen Salubris Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shenzhen Salubris Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Salubris Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amorepacific Corp. (New)
KO:090430
|
-0.005x |
|
Davide Campari-Milano N.V
PINK:DVDCF
|
0.045x |
|
PETRONAS Gas Berhad
PINK:PNAGF
|
0.044x |
|
Avanza Bank Holding AB (publ)
ST:AZA
|
1.029x |
|
Core Scientific, Inc. Tranche 2 Warrants
NASDAQ:CORZZ
|
-0.117x |
|
Kadant Inc
NYSE:KAI
|
0.054x |
|
Franklin Electric Co Inc
NASDAQ:FELE
|
0.078x |
|
KION GROUP AG
OTCGREY:KNNGF
|
0.037x |
Annual Cash Flow Conversion Efficiency for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥8.75 Billion | CN¥1.19 Billion | 0.136x | +25.52% |
| 2023-12-31 | CN¥8.06 Billion | CN¥869.79 Million | 0.108x | -11.28% |
| 2022-12-31 | CN¥7.98 Billion | CN¥970.80 Million | 0.122x | -17.36% |
| 2021-12-31 | CN¥8.05 Billion | CN¥1.18 Billion | 0.147x | -40.08% |
| 2020-12-31 | CN¥5.59 Billion | CN¥1.37 Billion | 0.246x | +8.75% |
| 2019-12-31 | CN¥6.67 Billion | CN¥1.51 Billion | 0.226x | +15.83% |
| 2018-12-31 | CN¥6.87 Billion | CN¥1.34 Billion | 0.195x | -17.57% |
| 2017-12-31 | CN¥6.16 Billion | CN¥1.46 Billion | 0.237x | -9.93% |
| 2016-12-31 | CN¥5.46 Billion | CN¥1.43 Billion | 0.263x | +16.85% |
| 2015-12-31 | CN¥4.70 Billion | CN¥1.06 Billion | 0.225x | -13.27% |
| 2014-12-31 | CN¥3.79 Billion | CN¥982.25 Million | 0.259x | +21.59% |
| 2013-12-31 | CN¥3.13 Billion | CN¥668.52 Million | 0.213x | +6.65% |
| 2012-12-31 | CN¥2.61 Billion | CN¥521.21 Million | 0.200x | +56.74% |
| 2011-12-31 | CN¥2.13 Billion | CN¥272.32 Million | 0.128x | +27.50% |
| 2010-12-31 | CN¥1.87 Billion | CN¥186.65 Million | 0.100x | +20.96% |
| 2009-12-31 | CN¥1.62 Billion | CN¥134.28 Million | 0.083x | -72.08% |
| 2008-12-31 | CN¥262.90 Million | CN¥77.89 Million | 0.296x | -18.02% |
| 2007-12-31 | CN¥145.96 Million | CN¥52.75 Million | 0.361x | +220.57% |
| 2006-12-31 | CN¥106.48 Million | CN¥12.00 Million | 0.113x | -- |